18 Jan EG 427
Philippe Chambon, M.D., Ph.D., CEO
Paris, France
(Private)
EG 427 is the global leader in non-replicating HSV-1 (nrHSV-1) vectors in neurology. EG 427 has started a phase1/2 study in the US with its lead DNA medicine candidate, EG110A, in patients with neurogenic detrusor overactivity-related incontinence. This is the first human study with an nrHSV-1 vector targeting sensory neuron-based diseases. EG110A is being developed to addresses multiple severe bladder diseases and has the potential to be a major improvement over existing therapies, resulting in better care for patients and lower costs for healthcare systems. The company’s unique HERMES platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Its vectors can achieve focal transduction in specific regions and selective transgene expression in targeted subsets of neurons. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows for versatile DNA delivery for smarter DNA medicine.
